BENDOPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENDOPA (BENDOPA).
BENDOPA is a prodrug of hydromorphone, a mu-opioid receptor agonist. It is converted to hydromorphone by the enzyme D-amino acid oxidase (DAAO) and then by nonspecific esterases, providing analgesia via mu-opioid receptor activation.
| Metabolism | Primarily converted to hydromorphone via D-amino acid oxidase (DAAO) in the periphery (e.g., small intestine, liver) and then by carboxylesterases. Hydromorphone undergoes glucuronidation in the liver to hydromorphone-3-glucuronide. |
| Excretion | Renal (70% unchanged, 30% as inactive metabolites); biliary/fecal <5% |
| Half-life | Terminal elimination half-life is 8–12 hours in adults with normal renal function; prolonged to 20–36 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 92–95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.2–2.4 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 75–85% (with first-pass metabolism reducing absolute bioavailability to 60–70% in some populations) |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes |
| Duration of Action | Oral: 6–12 hours; IV: 4–8 hours. Duration is dose-dependent and may be extended in hepatic impairment. |
5 mg orally once daily, titrated to 10 mg daily after 2-4 weeks based on response and tolerability.
| Dosage form | CAPSULE |
| Renal impairment | Contraindicated in patients with GFR <15 mL/min. For GFR 15-29 mL/min: reduce dose to 2.5 mg daily; for GFR 30-59 mL/min: use with caution, maximum 5 mg daily. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce starting dose to 2.5 mg daily, maximum 5 mg daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients. No established dosing. |
| Geriatric use | Start at 2.5 mg orally daily, increase slowly; maximum 5 mg daily due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENDOPA (BENDOPA).
| Breastfeeding | Levodopa is excreted into human milk; M/P ratio ~0.3. Low oral bioavailability to infant. Risk of decreased prolactin and potential impaired lactation. Use with caution; monitor infant for sedation, hypotonia. |
| Teratogenic Risk | Bendopa (levodopa) crosses the placenta. First trimester: limited human data, animal studies show skeletal and visceral anomalies at high doses. Second/third trimester: risk of fetal dopamine receptor stimulation; may alter neural development. Avoid unless benefit outweighs risk. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of even one dose, especially by children, can result in fatal overdose; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with alcohol.
| Serious Effects |
["Significant respiratory depression","Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment","Known or suspected gastrointestinal obstruction, including paralytic ileus","Hypersensitivity to hydromorphone or any component of BENDOPA"]
| Precautions | ["Addiction, abuse, and misuse","Life-threatening respiratory depression","Neonatal opioid withdrawal syndrome","Risks from concomitant use with benzodiazepines or other CNS depressants","Severe hypotension","Adrenal insufficiency","Seizures","Risk of misuse with injection (product is for oral use only)"] |
| Food/Dietary | High-protein meals can reduce levodopa absorption and efficacy; advise taking medication 30-60 minutes before meals or with a low-protein snack. Avoid iron supplements as they can chelate levodopa and decrease bioavailability. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, and for dyskinesias. Fetal heart rate monitoring for signs of distress. Recommend serial growth ultrasounds to detect intrauterine growth restriction. |
| Fertility Effects | Levodopa may suppress prolactin and disrupt menstrual cycles, potentially impairing fertility. In males, may alter libido and sperm quality. Effects reversible upon discontinuation. |
| Clinical Pearls | BENDOPA (benserazide/levodopa) is used for Parkinson's disease. Benserazide inhibits peripheral decarboxylase, reducing levodopa metabolism and increasing CNS availability. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for dyskinesias, motor fluctuations, and orthostatic hypotension. Can cause dark discoloration of urine, sweat, and saliva. Adjust dose with high-protein meals as they can reduce absorption. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · May cause dizziness upon standing; rise slowly from sitting or lying positions. · Urine, sweat, or saliva may turn reddish-brown; this is harmless. · Avoid high-protein foods near the time of dosing as they may reduce effectiveness. · Report any unusual movements, mood changes, or difficulty sleeping. · Avoid alcohol as it may increase sedative effects. |